NCT02312193View on ClinicalTrials.gov

Evaluation of the Signaling Path of Emiline1-TGFβ in the Myogenic Tone of Resistance Arteries in a Population of Normotensive and Hypertensive Subjects

CompletedOBSERVATIONAL
Enrollment

95

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
Hypertension
Trial Locations (1)

86077

IRCCS Neuromed, Pozzilli

All Listed Sponsors
lead

Neuromed IRCCS

OTHER

NCT02312193 - Evaluation of the Signaling Path of Emiline1-TGFβ in the Myogenic Tone of Resistance Arteries in a Population of Normotensive and Hypertensive Subjects | Biotech Hunter | Biotech Hunter